Integra (IART) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Integra LifeSciences (IART) reported $368.87 million in revenue for the quarter ended March 2024, representing a year-over-year decline of 3.2%. EPS of $0.55 for the same period compares to $0.74 a year ago.

The reported revenue compares to the Zacks Consensus Estimate of $362.14 million, representing a surprise of +1.86%. The company has not delivered EPS surprise, with the consensus EPS estimate being $0.55.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Organic Revenue Growth: -2.5% versus the five-analyst average estimate of -4.5%.

• Revenue- Codman Specialty Surgical- Total: $256.43 million compared to the $251.49 million average estimate based on six analysts. The reported number represents a change of +3.3% year over year.

• Revenue- Tissue Technologies- Total: $112.44 million versus the six-analyst average estimate of $110.34 million. The reported number represents a year-over-year change of -15.3%.

• Revenue- Tissue Technologies- Private Label: $31.56 million versus $24.19 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -0.7% change.

• Revenue- Codman Specialty Surgical- Instruments: $54.17 million versus $58.47 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -2% change.

• Revenue- Codman Specialty Surgical- Neurosurgery: $202.27 million versus $192.94 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +4.9% change.

• Revenue- Tissue Technologies- Wound Reconstruction and Care: $80.88 million versus the four-analyst average estimate of $86.46 million. The reported number represents a year-over-year change of -19.9%.

View all Key Company Metrics for Integra here>>>

Shares of Integra have returned -15% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research